Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTA evaluation of retinal microvascular changes in central retinal vein occlusion before and after ranibizumab
PACTR202512755596999Phase 4Completed
- Sponsor
- Al-Azhar University
- Start
- Jan 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in central retinal vein occlusion (CRVO) (2 arms), sponsored by Al-Azhar University. Primary endpoints: Foveal avascular zone area, Superficial vessel density and 1 more. Started Jan 2024; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on PACTR202512755596999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202512755596999.